{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:36:38Z","timestamp":1762673798305},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Primary Care: Clinics in Office Practice"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.pop.2010.07.008","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T04:12:51Z","timestamp":1288757571000},"page":"703-711","source":"Crossref","is-referenced-by-count":3,"title":["Crystal Arthropathies: Recognizing and Treating \u201cThe Gouch\u201d"],"prefix":"10.1016","volume":"37","author":[{"given":"David M.","family":"Quillen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pop.2010.07.008_bib1","series-title":"Like Charlemagne, you\u2019ve got gout","author":"Gower","year":"2005"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pop.2010.07.008_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pop.2010.07.008_bib4","first-page":"30","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/BOR.0b013e3282f524a2","article-title":"Lifestyle and gout","volume":"20","author":"Hak","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.bor.0000209434.82096.1f","article-title":"Recent developments in diet and gout","volume":"18","author":"Lee","year":"2006","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 5","key":"10.1016\/j.pop.2010.07.008_bib7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3949\/ccjm.75.Suppl_5.S5","article-title":"Clinical manifestations of hyperuricemia and gout [review]","volume":"75","author":"Mandell","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"10.1016\/j.pop.2010.07.008_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"issue":"17","key":"10.1016\/j.pop.2010.07.008_bib9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pop.2010.07.008_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1503\/cmaj.080183","article-title":"Acute monoarthritis: what is the cause of my patient\u2019s painful swollen joint?","volume":"180","author":"Ma","year":"2009","journal-title":"CMAJ"},{"issue":"10","key":"10.1016\/j.pop.2010.07.008_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pop.2010.07.008_bib13","article-title":"An old gout drug gets a new life and a new price, riling patients","author":"Rockoff","year":"2010","journal-title":"Wall St J"},{"issue":"9627","key":"10.1016\/j.pop.2010.07.008_bib14","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pop.2010.07.008_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200868040-00002","article-title":"Overview of the management of acute gout and the role of adrenocorticotropic hormone","volume":"68","author":"Schlesinger","year":"2008","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.pop.2010.07.008_bib16","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.pop.2010.07.008_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.amjmed.2006.02.044","article-title":"Updates in the management of gout","volume":"120","author":"Keith","year":"2007","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A\u00a0critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.pop.2010.07.008_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.pop.2010.07.008_bib20","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A\u00a0randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.pop.2010.07.008_bib21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.pop.2010.07.008_bib22","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"Engl J Med"},{"issue":"11","key":"10.1016\/j.pop.2010.07.008_bib23","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.pop.2010.07.008_bib25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.pop.2010.07.008_bib26","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"18","key":"10.1016\/j.pop.2010.07.008_bib27","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2165\/00003495-200262180-00006","article-title":"Etoricoxib","volume":"62","author":"Cochrane","year":"2002","journal-title":"Drugs"}],"container-title":["Primary Care: Clinics in Office Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454310000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454310000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T21:56:20Z","timestamp":1544133380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095454310000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0095454310000758"],"URL":"https:\/\/doi.org\/10.1016\/j.pop.2010.07.008","relation":{},"ISSN":["0095-4543"],"issn-type":[{"value":"0095-4543","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}